Navigating the Complex Landscape of Antibiotic Development

This chapter explores the challenges faced by pharmaceutical companies in developing new antibiotics, focusing on the tension between essential public health needs and the business model's sustainability. It highlights the case of Zenlet, an antibiotic for bacterial pneumonia, and raises critical questions about drug pricing and company strategies in a market with uncertain financial returns.